Society of Cannabis Clinicians

Educating Healthcare Professionals
About the Medical Use of Cannabis

Who We Are

The SCC is a nonprofit educational and scientific society of healthcare professionals and allies dedicated to advancing research and disseminating knowledge about medical cannabis.

Physician Locator Map

Are you looking for a cannabis-knowledgable physician? Are you a healthcare provider wanting to highlight your practice? Our Locator Map guides prospective patients to clinician members.

Research Library

The SCC supports the practice of evidence-based cannabinoid medicine. All articles in the collection have been vetted to ensure only rigorous, unbiased, and non-commercialized studies are included.

COURSE OFFERINGS

Latest News

,

Terpenes and Cannabidiol against Human Corona and Influenza Viruses – Anti-Inflammatory and Antiviral in Vitro Evaluation

The activity of the terpenes and Cannabidiol (CBD) against human coronavirus (HCoV) strain OC43 and influenza A (H1N1) was evaluated in human lung fibroblasts (MRC-5 cells). Also, we examined whether these ingredients inhibit pro-inflammatory cytokines in peripheral blood mononuclear cells (PBMC). The tested preparations exhibited both anti-inflammatory and antiviral effects. The combination of terpenes was effective against both HCoV-OC43 and influenza A (H1N1) virus. The addition of CBD improved the antiviral activity in some, but not all cases. This variation in activity may suggest an antiviral mechanism. In addition, there was a strong correlation between the quantitative results from a cell-viability assay and the cytopathic effect after 72 h, as observed under a microscope. The anti-inflammatory properties of terpenes were demonstrated using a pro-inflammatory cytokine-inhibition assay, which revealed significant cytokine inhibition and enhanced by the addition of CBD.
,

Cannabinoids and the Endocannabinoid System in Early SARS-CoV-2 Infection and Long COVID-19—A Scoping Review

Coronavirus disease-19 (COVID-19) is a highly contagious illness caused by the SARS-CoV-2 virus. The clinical presentation of COVID-19 is variable, often including symptoms such as fever, cough, headache, fatigue, and an altered sense of smell and taste. Recently, post-acute “long” COVID-19 has emerged as a concern, with symptoms persisting beyond the acute infection. Vaccinations remain one of the most effective preventative methods against severe COVID-19 outcomes and the development of long-term COVID-19. However, individuals with underlying health conditions may not mount an adequate protective response to COVID-19 vaccines, increasing the likelihood of severe symptoms, hospitalization, and the development of long-term COVID-19 in high-risk populations. This review explores the potential therapeutic role of cannabinoids in limiting the susceptibility and severity of infection, both pre- and post-SARS-CoV-19 infection.

Job Opportunity: Cannabis Ombudsperson for the State of Connecticut

The State of Connecticut, Office of the Healthcare Advocate (OHA) is recruiting for a Cannabis Ombudsperson position in Hartford,…

Board Member at Asia International Hemp Forum

Dr. Shiksha Gallow, one of the Board members of the SCC, was invited as one of the global keynote speakers at the Asia…

Does Cannabis Cause Heart Failure and Stroke?

Does Cannabis Cause Heart Failure and Stroke? You may have seen the recent headlines about two new studies that found…
,

Broad-Spectrum Antiviral Effect of Cannabidiol Against Enveloped and Nonenveloped Viruses

Cannabidiol (CBD), the main non-psychoactive cannabinoid of the Cannabis sativa plant, is a powerful antioxidant compound that in recent years has increased interest due to causes effects in a wide range of biological functions. Zika virus (ZIKV) is a virus transmitted mainly by the Aedes aegypti mosquitoes, which causes neurological diseases, such as microcephaly and Guillain-Barre syndrome. Although the frequency of viral outbreaks has increased recently, no vaccinations or particular chemotherapeutic treatments are available for ZIKV infection. The major aim of this study was to explore the in vitro antiviral activity of CBD against ZIKV, expanding also to other dissimilar viruses.
21 years

As an organization

38 States

Members practice in

24 Countries

Our members represent

737 Articles

in the Research Library

Membership & Online Learning

Membership information

Diversity within the SCC is critical to our success and ability to educate each other. Healthcare professionals and allies are welcome to join, including (but not limited to): physicians, nurses, pharmacists, caregivers, veterinarians, herbalists, physical therapists, researchers, and patients.

Video Library

View our robust collection of presentations by leading international experts sharing cannabis science and medical applications. There are various free options available to everyone. Full videos of quarterly meetings and other exclusive content is viewable in the Members Portal.

O’Shaughnessy’s Journal

SCC Founder Tod Mikuriya, MD was a physician, researcher, and creator of a new “Cannabis Clinician” specialty. Tod envisioned a journal where clinicians monitoring patients’ cannabis use could share observations. O’Shaughnessy’s continues to this day.

Global Impact

Affiliates & Allies